Target
RAD51D
26 products, 24 indications
Indications
Metastatic Castration-Resistant Prostate Cancer (5 products)
Platinum-sensitive recurrent ovarian carcinoma (4 products)
Advanced Epithelial Ovarian Cancer (3 products)
high grade serous ovarian carcinoma (2 products)
Ovarian Cancer (2 products)
Advanced high-grade ovarian cancer (2 products)
Platinum-resistant recurrent ovarian carcinoma (2 products)
metastatic hormone-resistant prostate cancer (1 products)
Endometrial and ovarian cancer (1 products)
advanced HER2 negative gastric, esophageal, and gastroesophageal junction adenocarcinoma (1 products)
Ovarian cancer, primary peritoneal cancer, fallopian tube cancer (1 products)
recurrent or metastatic head and neck squamous cell carcinoma (1 products)
recurrent or metastatic cervical cancer (1 products)
high-grade stage III/IV ovarian cancer (1 products)
metastatic hormone sensitive prostate cancer (1 products)
recurrent high-grade ovarian, fallopian tube and primary peritoneal cancer (1 products)
Recurrent PARPi-resistant ovarian cancer (1 products)
platinum-resistant/refractory epithelial ovarian cancer (1 products)
relapsed/refractory NSCLC (1 products)
platinum-resistant high-grade serous ovarian cancer (1 products)
HRD-positive recurrent platinum-resistant epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (1 products)
metastatic non-small cell lung cancer (1 products)
Stage III melanoma (1 products)
glioblastoma (1 products)
Loading...
1 drug
15 abstracts
Abstract
PROact: A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in patients with metastatic hormone sensitive prostate cancer with HRR gene mutation.Org: Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Institute of Urology, Nanjing University, Nanjing, China,
Abstract
Association between homologous recombination deficiency (HRD) gene mutations and the efficacy of venadaparib in combination with irinotecan as third- or fourth-line treatment in patients with metastatic gastric cancer (mGC).Org: Idience Inc.,
Abstract
Detection of homologous recombination deficiency (HRD) using a novel genomic and epigenomic liquid biopsy assay in patients with breast cancer.Org: Guardant Health Inc., Guardant Health, Inc.,
Abstract
Olaparib (O) + ceralasertib (C) in patients (pts) with metastatic triple-negative breast cancer (mTNBC): Translational analysis of the VIOLETTE trial.Org: AstraZeneca, University Hospitals Leuven, Leuven, Belgium, The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Seoul National University College of Medicine, Christie Hospital NHS Foundation Trust and the University of Manchester,
Abstract
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.Org: Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).Org: University of Kansas Cancer Center, Kansas City, KS, Westwood, The University of Kansas Medical Center, Kansas City, MO, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Hereditary breast and ovarian cancer syndrome: A misnomer?Org: New York Medical College - Saint Michael's Medical Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
Women with pathogenic variants in moderate penetrance breast cancer genes: How frequently do they meet high penetrance genetic testing criteria?Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, Institute for Genomic Health, 23andMe Inc., Sunnyvale, CA,
Abstract
Eliminating barriers to uptake of germline genetic testing for patients with advanced cancer: The GTAC study.Org: University of Vermont Larner College of Medicine, University of Vermont Cancer Center, Invitae, University of Colorado Denver Anschutz Medical Center,
Abstract
Disparities in minority patients with breast cancer under 40 years of age: A single center experience.Org: UT Austin Dell Medical School, Ascension Seton,
Abstract
Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.Org: Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy, Department of Surgical Oncological and Oral Sciences, Palermo, Italy, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy, Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy, Azienda Ospedaliera Universitaria "P.Giaccone", Palermo, Italy, Department of Surgical Oncological and Oral Sciences; University of Palermo, Palermo, Italy, Proteomics Group of Fondazione Ri.MED, Department of Research IRCCS ISMETT, 90145 Palermo, Italy, Palermo, Italy, University School of Medicine, Palermo, Italy, A.O.U. Policlinico P. Giaccone, Palermo, Italy, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy, Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, University of Palermo, Palermo, Italy,
Abstract
3D genomics identifies previously unreported yet clinically actionable gene fusions and complex rearrangements in a cohort of driver-negative colorectal carcinoma tumors.Org: Arima Genomics, Scripps Clinic/Green Hospital, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Scripps Clinic and Scripps MD Anderson Cancer Center,
Abstract
3D genomics identify alternate mechanisms of homologous recombination deficiency in uterine sarcoma.Org: Memorial Sloan Kettering Cancer Center, New York, NY, NYU Langone Health, New York, NY, King Edward Memorial Hospital, Perth, Australia,
Abstract
Phenotypic differences related to homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) treated in routine care settings in the United States (US).Org: Merck & Co., Inc., Merck and Co., Inc, Integra Connect PrecisionQ,
Drug
Olaparib